228 related articles for article (PubMed ID: 12719441)
1. Different effect of antihypertensive drugs on conduit artery endothelial function.
Ghiadoni L; Magagna A; Versari D; Kardasz I; Huang Y; Taddei S; Salvetti A
Hypertension; 2003 Jun; 41(6):1281-6. PubMed ID: 12719441
[TBL] [Abstract][Full Text] [Related]
2. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Fox KM;
Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
Ichikawa Y
Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
[TBL] [Abstract][Full Text] [Related]
5. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Køber L; Torp-Pedersen C; Carlsen JE; Bagger H; Eliasen P; Lyngborg K; Videbaek J; Cole DS; Auclert L; Pauly NC
N Engl J Med; 1995 Dec; 333(25):1670-6. PubMed ID: 7477219
[TBL] [Abstract][Full Text] [Related]
6. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
Pfeffer MA; Braunwald E; Moyé LA; Basta L; Brown EJ; Cuddy TE; Davis BR; Geltman EM; Goldman S; Flaker GC
N Engl J Med; 1992 Sep; 327(10):669-77. PubMed ID: 1386652
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan versus valsartan in patients with hypertension: effects on cardiovascular, metabolic, and inflammatory parameters.
Lim SY; Kim SW; Kim EJ; Kang JH; Kim SA; Kim YK; Na JO; Choi CU; Lim HE; Han SW; Rha SW; Park CG; Seo HS; Oh DJ
Korean Circ J; 2011 Oct; 41(10):583-9. PubMed ID: 22125557
[TBL] [Abstract][Full Text] [Related]
8. Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients.
Hasegawa H; Takano H; Narumi H; Ohtsuka M; Mizuguchi T; Namiki T; Kobayashi Y; Komuro I
Hypertens Res; 2011 Nov; 34(11):1179-84. PubMed ID: 21796128
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
Hong SJ; Choi SC; Ahn CM; Park JH; Kim JS; Lim DS
Heart; 2011 Sep; 97(17):1425-32. PubMed ID: 21700754
[TBL] [Abstract][Full Text] [Related]
10. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
12. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients.
de Luis DA; Conde R; González-Sagrado M; Aller R; Izaola O; Dueñas A; Pérez Castrillón JL; Romero E
Nutr Hosp; 2010; 25(2):275-9. PubMed ID: 20449538
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance.
Perl S; Schmölzer I; Sourij H; Pressl H; Eder M; Zweiker R; Wascher TC
Int J Cardiol; 2010 Mar; 139(3):289-96. PubMed ID: 19118910
[TBL] [Abstract][Full Text] [Related]
14. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
Metabolism; 2008 Oct; 57(10):1473-8. PubMed ID: 18803955
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
[TBL] [Abstract][Full Text] [Related]
17. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
[TBL] [Abstract][Full Text] [Related]
18. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.
Negro R; Formoso G; Hassan H
J Endocrinol Invest; 2006 Dec; 29(11):957-61. PubMed ID: 17259791
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.
Vitale C; Mercuro G; Castiglioni C; Cornoldi A; Tulli A; Fini M; Volterrani M; Rosano GM
Cardiovasc Diabetol; 2005 May; 4():6. PubMed ID: 15892894
[TBL] [Abstract][Full Text] [Related]
20. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up.
Zaugg M; Bestmann L; Wacker J; Lucchinetti E; Boltres A; Schulz C; Hersberger M; Kälin G; Furrer L; Hofer C; Blumenthal S; Müller A; Zollinger A; Spahn DR; Borgeat A
Anesthesiology; 2007 Jul; 107(1):33-44. PubMed ID: 17585213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
